Effect of insulin treatment on plasma oxidized LDL/LDL-cholesterol ratio in type 2 diabetic patients

Diabetes and Metabolism

Volumn 32, Issue 6, 2006, Pages 625-631

  Galland, F ^a   Duvillard, L ^a   Petit, J M ^a   Lagrost, L ^a   Vaillant, G ^a   Brun, J M ^a   Gambert, P ^a   Verges B ^a  

^a HÔPITAL DU BOCAGE   (France)

Author keywords

Atherosclerosis; Insulin; Lipoproteins; Oxidized LDL; Type 2 diabetes

Indexed keywords

FRUCTOSAMINE; GLIBENCLAMIDE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; METFORMIN; OXIDIZED LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCATION; HUMAN; INSULIN TREATMENT; LIPID BLOOD LEVEL; MALE; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS;

EID: 33846444030     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1262-3636(07)70318-X     Document Type: Article

References (46)

1. Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-44.
2. Garcia MJ, McNamara PM, Gordon T, et al. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. Diabetes 1974;23:105-11.
3. Bierman EL. George Lyman Duff Memorial Lecture. Atherogenesis in diabetes. Arterioscler Thromb 1992;12:647-56.
4. Taskinen MR: Quantitative and qualitative lipoprotein abnormalities in diabetes mellitus. Diabetes 1992;41(Suppl. 2):12-7.
5. Lopes-Virella MF, Klein RL, Virella G. Modification of lipoproteins in diabetes. Diabetes Metab Rev 1996;12:69-90.
6. Vergès BL. Dyslipidaemia in diabetes mellitus. Review of the main lipoprotein abnormalities and their consequences on the development of atherogenesis. Diabetes Metab 1999;25(Suppl. 3):32-40.
7. Haffner SM, Mykkanen L, Stern MP, et al. Greater effect of diabetes on LDL size in women than in men. Diabetes Care 1994;17:1164-71.
8. Feingold KR, Grunfeld C, Pang M, et al. LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes. Arterioscler Thromb 1992;12:1496-502.
9. Kim HJ, Kurup IV. Nonenzymatic glycosylation of human plasma low density lipoprotein. Evidence for in vitro and in vivo glucosylation. Metabolism 1982;31:348-53.
10. Lyons TJ, Jenkins AJ. Lipoprotein glycation and its metabolic consequences. Curr Opin Lipidol 1997;8:174-180.
11. Guerci B, Antebi H, Meyer L, et al. Increased ability of LDL from Normolipidemic Type 2 Diabetic Women to Generate Peroxides. Clin Chem 1999;45:1439-48.
12. Steinberg D, Parthasarathy S, Carew TE, et al. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989;320:915-924.
13. Oranje WA, Wolffenbuttel BH. Lipid peroxidation and atherosclerosis in type II diabetes. J Lab Clin Med 1999;134:19-32.
14. Toshima S, Hasegawa A, Kurabayashi M, et al. Circulating oxidized low density lipoprotein levels. A biochemical risk marker for coronary heart disease. Arterioscler Thromb Vasc Biol 2000;20:2243-7.
15. Kopprasch S, Pietzsch J, Kuhlisch E, et al. In vivo evidence for increased oxidation of circulating LDL in impaired glucose tolerance. Diabetes 2002;1:3102-6.
16. Tsuzura S, Ikeda Y, Suehiro T, et al. Correlation of plasma oxidized low-density lipoprotein levels to vascular complications and human serum paraoxonase in patients with type 2 diabetes. Metabolism 2004;53:297-302.
17. Vergès B. Insulin sensitiviy and lipids. Diabetes Metab 2001;27:223-7.
18. Jackson TK, Salhanick AI, Elovson J, et al. Insulin regulates apolipoprotein B turnover and phosphorylation in rat hepatocytes. J Clin Invest 1990;86:1746-51.
19. Salhanick AI, Schwartz SI, Amatruda JM. Insulin inhibits apolipoprotein B secretion in isolated human hepatocytes. Metabolism 1991;40:275-9.
20. Lewis GF, Uffelman KD, Szeto LW, et al. Effects of acute hyperinsulinemia on VLDL triglyceride and VLDL apoB production in normal weight and obese individuals. Diabetes 1993;42:833-42.
21. Malmstrom R, Packard CJ, Caslake M, et al. Effects of insulin and acipimox on VLDL1 and VLDL2 apolipoprotein B production in normal subjects. Diabetes 1998;47:779-87.
22. Chait A, Bierman EL, Albers JJ. Low-density lipoprotein receptor activity in cultured human skin fibroblasts. Mechanism of insulin-induced stimulation. J Clin Invest 1979;64:1309-19.
23. Mazzone T, Foster D, Chait A. In vivo stimulation of low-density lipoprotein degradation by insulin. Diabetes 1984;33:333-8.
24. Kraemer FB, Sather SA, Park B, et al. Low density lipoprotein receptors in rat adipose cells: subcellular localization and regulation by insulin. J Lipid Res 1994;35:1760-72.
25. Streicher R, Kotzka J, Muller-Wieland D, et al. SREBP-1 mediates activation of the low density lipoprotein receptor promoter by insulin and insulin-like growth factor-I. J Biol Chem 1996;271:7128-33.
26. Duvillard L, Pont F, Florentin E, et al. Significant improvement of apolipoprotein B-containing lipoprotein metabolism by insulin treatment in patients with non-insulin-dependent diabetes mellitus. Diabetologia 2000;43:27-35.
27. Taskinen MR, Kuusi T, Helve E, et al. Insulin therapy induces antiatherogenic changes of serum lipoproteins in noninsulin-dependent diabetes. Arteriosclerosis 1988;8:168-77.
28. Agardh CD, Nilsson-Ehle P, Schersten B. Improvement of the plasma lipoprotein pattern after institution of insulin treatment in diabetes mellitus. Diabetes Care 1982;5:322-5.
29. Duvillard L, Florentin E, Lizard G et al. Cell surface expression of LDL receptor is decreased in type 2 diabetic patients and is normalized by insulin therapy. Diabetes Care 2003;26:1540-4.
30. Duvillard L, Pont F, Florentin E et al. Metabolic abnormalities of apolipoprotein B-containing lipoproteins in non-insulin-dependent diabetes: a stable isotope kinetic study. Eur J Clin Invest 2000;30:685-94.
31. Stephens JW, Gable DR, Hurel SJ et al. Increased plasma markers of oxidative stress are associated with coronary heart disease in males with diabetes mellitus and with 10-years risk in a prospective sample of males. Clin Chem; 2006;52:446-52.
32. Holvoet P, Vanhaecke J, Janssens S, et al. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 1998;98:1487-94.
33. Holvoet P, Kritchevsky SB, Tracy RP, et al. The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-functioning elderly people in the health, aging, and body composition cohort. Diabetes 2004;53:1068-73.
34. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
35. Viens L, Athias A, Lizard G et al. Effect of lipid transfer activity and lipolysis on low density lipoprotein (LDL) oxidizability: evidence for lipolysis-generated non-esterified fatty acids as inhibitors of LDL oxidation. J Lipid Res 1996;37:2179-92.
36. Holvoet P, Mertens A, Verhamme P et al. Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2001;21:844-8.
37. Oranje WA, Rondas-Colbers GJ, Swennen GN et al. Lipid peroxidation in type 2 diabetes: relationship with macrovascular disease? Neth J Med 1998;53:61-8.
38. Austin MA. Small, dense low-density lipoprotein as a risk factor for coronary heart disease. Int J Clin Lab Res 1994;24:187-92.
39. Bowie A, Owens D, Collins P et al. Glycosylated low density lipoprotein is more sensitive to oxidation: implications for the diabetic patient? Atherosclerosis 1993;102:63-7.
40. Kondo S, Manabe M, Saito K, Maekawa M et al. Insulin Treatment Prevents LDL from Accelerated Oxidation in patients with diabetes. J Atheroscler Thromb; 2002;9:280-7.
41. Makimattila S, Liu ML, Vakkilainen J, et al. Impaired endothelium-dependent vasodilation in type 2 diabetes. Relation to LDL size, oxidized LDL, and antioxidants. Diabetes Care; 1999;22:973-81.
42. Tribble DL, Holl LG, Wood PD, Krauss RM. Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis 1992;93:189-99.
43. Hansen TK, Thiel S, Wouters PJ, et al. Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. J Clin Endocrinol Metab 2003;88:1082-8.
44. Dandona P, Aljada A, Mohanty P, et al. Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? J Clin Endocrinol Metab 2001;86:3257-65.
45. Das UN. Is insulin an antiinflammatory molecule? Nutrition 2001;17:409-13.
46. Satomi N, Sakurai A, Haranaka K. Relationship of hypoglycemia to tumor necrosis factor production and antitumor activity: role of glucose, insulin, and macrophages. J Natl Cancer Inst 1985;74:1255-60.